Is betahistine effective for Ménière s disease?
A Rosenbaum, M Winter - Medwave, 2017
... Angelini, Avda. Vicuña Mackenna 4860, Macul, Santiago, Chile. PROBLEM: Meniere
s disease is an inner ear disorder characterized by episodes of spontaneous vertigo,
fluctuating hearing loss and tinnitus. Betahistine has ...
s disease is an inner ear disorder characterized by episodes of spontaneous vertigo,
fluctuating hearing loss and tinnitus. Betahistine has ...
[HTML] Longitudinal up‐regulation of endolymphatic hydrops in patients with Meniere's disease during medical treatment
M Fukushima, T Kitahara, R Oya, S Akahani, H Inohara… - Laryngoscope Investigative …, 2017
Methods Eleven MD patients were enrolled. All subjects prospectively underwent
gadolinium-enhanced inner ear magnetic resonance (MR) imaging and neuro-otological
testing before and after medical treatment. The volume of EH was quantitatively evaluated
gadolinium-enhanced inner ear magnetic resonance (MR) imaging and neuro-otological
testing before and after medical treatment. The volume of EH was quantitatively evaluated
Clinical Pharmacology of Tinnitus: Design and Evaluation
AJ Szczepek - 2017
... Illnesses capable of inducing subjective tinnitus include, but are not limited to, the head and neck
injuries and all diseases that induce hearing impairment (middle ear inflammation, meningitis,
otosclerosis, Meniere's disease, pre- sbyacusis, ototoxicity, noise-induced hearing ...
injuries and all diseases that induce hearing impairment (middle ear inflammation, meningitis,
otosclerosis, Meniere's disease, pre- sbyacusis, ototoxicity, noise-induced hearing ...
[HTML] A Novel Nano-approach for Targeted Inner Ear Imaging
MN Kayyali, L Brake, AJ Ramsey, AC Wright… - Journal of nanomedicine & …, 2017
... These agents have enabled endolymphatic hydrops associated with Meniere's disease to be
detected [11,12]. ... Imaging of Meniere's disease after intravenous administration of single-dose
gadodiamide: utility of subtraction images with different inversion time. ...
detected [11,12]. ... Imaging of Meniere's disease after intravenous administration of single-dose
gadodiamide: utility of subtraction images with different inversion time. ...
METHODS FOR TREATMENT OF DISEASE USING GALVANIC VESTIBULAR STIMULATION
PD Mcgeoch, VS Ramachandran - US Patent 20,170,304,616, 2017
... Sailesh & Mukkadan, 2014). A chemical approach to vestibular stimulation may be
based on betahistine, a partial histamine-3 (H3) receptor antagonist that has been
used for some time to treat Meniere's disease. It is also known ...
based on betahistine, a partial histamine-3 (H3) receptor antagonist that has been
used for some time to treat Meniere's disease. It is also known ...
METHOD AND SYSTEM FOR ALTERING BODY MASS COMPOSITION USING GALVANIC VESTIBULAR STIMULATION
PD Mcgeoch, VS Ramachandran - US Patent 20,170,304,618, 2017
... Sailesh & Mukkadan, 2014). A chemical approach to vestibular stimulation may be
based on betahistine, a partial histamine-3 (H3) receptor antagonist that has been
used for some time to treat Meniere's disease. It is also known ...
based on betahistine, a partial histamine-3 (H3) receptor antagonist that has been
used for some time to treat Meniere's disease. It is also known ...
[HTML] A Comparison of the Effects and Side Effects of Oral Betahistine with Injectable Promethazine in the Treatment of Acute Peripheral Vertigo in Emergency
H Motamed, M Moezzi, AD Rooyfard, KA Angali, Z Izadi - Journal of Clinical Medicine …, 2017
... 2003;123(5):588-593. doi pubmed; Fraysse B, Bebear JP, Dubreuil C, Berges C, Dauman R.
Betahistine dihydrochloride versus flunarizine. A double-blind study on recurrent vertigo with
or without cochlear syndrome typical of Meniere's disease. Acta Otolaryngol Suppl. ...
Betahistine dihydrochloride versus flunarizine. A double-blind study on recurrent vertigo with
or without cochlear syndrome typical of Meniere's disease. Acta Otolaryngol Suppl. ...
NOVEL AMINOPYRIDINE COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN PRENYLATION
M Peschanski, S Blondel, X Nissan - US Patent 20,170,305,892, 2017
A compound for use in the treatment and/or prevention of diseases or disorders
wherein an inhibition of protein prenylation is required, which is alternatively
chosen among <p><chemistry id="CHEM-US-0.
wherein an inhibition of protein prenylation is required, which is alternatively
chosen among <p><chemistry id="CHEM-US-0.
ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF
RJ Noelle, S Delong, M Molloy, C Carriere, J Rothstein… - US Patent 20,170,306,020, 2017
The invention provides agonistic anti-human VISTA antibodies and antibody
fragments. These agonist antibodies and antibody fragments may be used
to potentiate or enhance or mimic VISTA's suppressive e.
fragments. These agonist antibodies and antibody fragments may be used
to potentiate or enhance or mimic VISTA's suppressive e.
ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF
C Carriere, M Molloy, J Rothstein - US Patent 20,170,306,019, 2017
The invention provides agonistic anti-human VISTA antibodies and antibody
fragments. These agonist antibodies and antibody fragments may be used
to potentiate or enhance or mimic VISTA's suppressive e.
fragments. These agonist antibodies and antibody fragments may be used
to potentiate or enhance or mimic VISTA's suppressive e.
Αυτή η Ειδοποίηση του Μελετητή Google σας προσφέρεται από τη Google
Ακύρωση ειδοποίησης
Δημιουργία λίστας των ειδοποιήσεών μου
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου